Our own in vitro studies seemed to indicate that sunitinib, at concentrations identical to those promoting tumor cell apoptosis in conjunction with recombinant cytokines, also displayed a potent capacity to nearly ablate antigen-specific IFN-γ secretion in both the allogenic MLR and to specific protein recall antigens (Figure 6). This evidence concerns the gene IFNG and neoplasm.